David Lederer, M.D., M.S.

Herbert Irving Assistant Professor of Medicine and Epidemiology (in Pediatrics)
Associate Medical Director, Lung Transplant Program
Co-Director, Interstitial Lung Disease Program


Dr. Lederer is the Associate Medical Director of the New York Presbyterian Lung Transplant Program and Co-Director of the New York Presbyterian/Columbia University Interstitial Lung Disease Program. He is an attending physician at New York Presbyterian Hospital/Columbia where he cares for lung transplant recipients and patients with interstitial lung diseases, including idiopathic pulmonary fibrosis. He is the principal investigator of two NHLBI-funded studies: the MESA Lung Fibrosis Study and the Lung Transplant Body Composition Study. He is a Deputy Editor of the Annals of the American Thoracic Society and sits on the Editorial board of the American Journal of Respiratory and Critical Care Medicine.

Dr. Lederer's research focuses on two related areas (1) enhancing the understanding of the causes of lung fibrosis in humans, and (2) improving outcomes after lung transplantation by investigating and improving candidacy for the procedure. His leads research efforts in the following areas:

  • Causes of interstitial lung disease
  • Frailty and obesity in lung transplantation
  • Novel therapies for idiopathic pulmonary fibrosis
  • Disparities in deceased donor organ allocation
  • Obesity, sleep apnea, and lung injury

Education and Training

B.S. in Biology, Adelphi University, Garden City, NY, 1995
M.S., Biostatistics, Columbia University Mailman School of Public Health, 2007
Medical School:
SUNY Downstate College of Medicine, Brooklyn, NY, 1999
Department of Medicine, Columbia Presbyterian Medical Center, NY, NY, 1999-2000
Department of Medicine, Columbia Presbyterian Medical Center, 2000-2002
Chief Residency:
Department of Medicine, Columbia Presbyterian Medical Center, 2002-2003
Pulmonary and Critical Care Fellow, Columbia Presbyterian Medical, Center, 2003-2005
Research Fellow, Columbia Presbyterian Medical Center, New York T32 HL072739; Mentor: Neil Schluger, M.D, 2005-2006.

Honors and Awards

  • 2008-11 Robert Wood Johnson Physician Faculty Scholar
  • 2008-11 Herbert and Florence Irving Scholar

Other Experience and Professional Membership

2011 – 14
American Lung Association, Research Training Fellowship Study Section (standing member)
2011 –
Advisory Board, POR Masters Degree Program, Irving Institute/Columbia CTSA
NIH/NHLBI ZHL1 CSR-F (M1): Mentoring programs to promote diversity in health research (K01/R25)
NIH/NHLBI ZHL1 CSR-P (F1): Maximizing the scientific value of the NHLBI biologic specimen repository: Scientific opportunities (R21)
2012 –
Member, ISHLT Lung Transplant Selection Guidelines Committee
2012 – 13
Member, NHLBI Primary Prevention of Chronic Lung Diseases Strategic Planning Workshop
2012 –
Deputy Editor, Annals of the American Thoracic Society
2013 –
Editorial Board, American Journal of Respiratory and Critical Care Medicine
NIH/NHLBI ZHL1 CSR-F (M1): Phase II Clinical Trials of Novel Therapies for Lung Disease (UM1)


For appointments: 

NYP/Columbia Lung Transplant Program
Columbia University Medical Center
622 W 168th Street, PH-14, Room 104
New York, NY 10032
Admin Assistant (Maylin): 212-305-6589
Fax: 212-342-5382

NYP/Columbia Interstitial Lung Disease Program
Columbia University Medical Center
622 W 168th Street, VC-3, Room 365
New York, NY 10032
Admin Assistant (Susanne): 212-305-8203
Fax: 212-305-8426


  • Pulmonary Disease Medicine
  • Lung Transplantation

Clinical Expertise

  • Interstitial lung disease
  • Idiopathic pulmonary fibrosis
  • Lung transplantation

Clinical Centers

Board Certifications

  • Internal Medicine Diplomate, 2002
  • Pulmonary Disease Diplomate, 2005
  • Critical Care Medicine Diplomate, 2006


Contact Information: 

Columbia Lung Transplant and Interstitial Lung Disease Research Program
Lederer Laboratory
Department of Medicine
Columbia University Medical Center
622 W 168th Street, PH-14, Room 404
New York, NY 10032
Project Coordinator (Nisha): 212-305-7720
Clinical Trials Coordinator (Tatiana): 212-342-4167
Grants Administrator (Cicely): 212-305-7074

Research Interests

  • Subclinical interstitial lung disease
  • Body composition and lung transplantation
  • Disparities in access to subspecialty pulmonary services and lung transplantation
  • Obstructive sleep apnea and alveolar injury


  • R01 HL103676 (Lederer) 04/15/2011 – 04/14/2015
    Subclinical Interstitial Lung Disease in MESA
    The Aims of this project are to validate high attenuation areas (HAA) on CT lung imaging as a marker of subclinical interstitial lung disease and perform genome wide association and linkage studies of HAA.
    Role: PI
  • R01 HL081619 (Christie) 02/15/2007 – 01/31/2013
    Genetics of Primary Graft Dysfunction
    This study aims to identify genetic predictors of predict primary graft failure after lung transplant.
    Role: Co-Investigator (Columbia site PI)
  • R01 HL087115 (Christie) 08/15/2007 – 07/31/2012
    Clinical Risk Factors for Primary Graft Dysfunction
    This is a study to identify clinical predictors of primary graft failure after lung transplantation.
    Role: Co-Investigator (Columbia site PI)
  • R25 HL105401 (Begg) 09/25/2010 – 07/31/2014
    FIRST in CER (Facilitating Independence in Research through the Summer Training in Comparative Effectiveness Research) Diversity Program
    This program provides summer training and mentoring in skills essential to conducting comparative effectiveness research (CER), enhancing the career development of faculty and scientists from diverse backgrounds in basic and applied sciences relevant to heart, lung, blood, and sleep disorders.
    Role: Collaborator
  • R25 HL096260 (Begg) 05/15/2009 – 04/30/2014
    BEST-DP: Biostatistics Enrichment Summer Training Diversity Program
    This program provides research opportunities in biostatistics, cardiovascular disease, and pulmonary disease for individuals who are under- represented in biomedical research (those from disadvantaged backgrounds, racial and ethnic minorities, and individuals with disabilities), and who will contribute to a more diverse research workforce in the future.
    Role: Collaborator
  • BI 1199.32 07/01/2011– 12/31/2015
    A 52 week, double-blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150mg twice daily, on annual FVC decline in patients with IPF
    This is a multicenter clinical trial of BIBF 1120 to treat IPF.
    Role: Columbia site PI
  • Irving Pilot Award 07/01/2012– 06/30/2013
    Irving Institute for Clinical and Translational Research (Columbia CTSA)
    Obesity, Lung Transplantation, and Lung Injury
    The major goal of this pilot study is to examine the use of quantitative CT imaging to ascertain adipose tissue distribution in lung transplant candidates.
    Role: PI
  • U01 HL105371 (Choi) 03/01/2012– 06/30/2014
    Phase II Study of Inhaled Carbon Monoxide for the Treatment of IPF
    The purpose of this study is test the safety and efficacy of inhaled carbon monoxide in IPF.
    Role: Co-investigator (Columbia site PI)
  • R01 HL114468 (Hancock) 05/15/2012 – 03/31/2016
    Foxp3+ Treg Cells & Primary Graft Dysfunction in Clinical Lung Tx Recipients
    The Aims of this project are to examine role of Treg cells in primary graft dysfunction after lung transplantation.
    Role: Co-investigator (Columbia site PI)

Selected Publications

  1. Baldwin, MR, Arcasoy SM, Shah A, Sze J, Sonett JR, Lederer DJ. Hypoalbuminemia and early mortality after lung transplantation: a cohort study. Am J Transplant 2012;12(5):1256-67.
  2. Hook JL, Arcasoy SM, Zemmel D, Bartels M, Kawut SM, Lederer DJ. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. Eur Respir J 2012;39(2):359-65.
  3. Lederer DJ, Kawut S, Wikersham N, Winterbottom C, Bhorade S, Palmer S, Lee J, Diamond J, Wille K, Weinacker A, Lama V, Crespo M, Orens J, Sonett J, Arcasoy S, Ware L, Christie J. Obesity and primary graft dysfunction after lung transplantation: the LTOG Obesity Study. Am J Respir Crit Care Med 2011;184:1055-61.
  4. Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, Lederer DJ. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011;184:842-7.
  5. Lederer DJ, Wilt JS, D’Ovidio F, Bacchetta M, Shah L, Ravichandran S, Lenoir J, Klein B, Sonett JR, Arcasoy SM. Obesity and underweight are associated with an increased risk of death after lung transplantation. Am J Respir Crit Care Med 2009;180(9):887-95.
  6. Lederer DJ, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, van Beek EJR, Austin JHM, Jiang R, Lovasi GS, Barr RG. Cigarette smoking is associated with subclinical parenchymal lung disease: The MESA-Lung Study. Am J Respir Crit Care Med 2009;180(5):407-14.
  7. Lederer DJ¸ Jelic S, Basner RC, Ishizaka A, Bhattacharya J. Circulating KL-6, a biomarker of lung injury, in obstructive sleep apnea. Eur Respir J 2009;33(4):793-6.
  8. Lederer DJ, Benn EKT, Barr RG, Wilt JS, Reilly G, Sonett JR, Arcasoy SM, Kawut SM. Racial differences in waiting list outcomes in COPD. Am J Respir Crit Care Med 2008;177(4):450-454.
  9. Lederer DJ, Arcasoy SM, Barr RG, Wilt JS, Bagiella E, D'Ovidio F, Sonett JR, Kawut SM. Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis. Am J Transplant 2006;6(10):2436-42.
  10. Lederer DJ, Caplan-Shaw CE, O’Shea MK, Wilt JS, Basner RG, Bartels MN, Sonett JR, Arcasoy SM, Kawut SM. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. Am J Transplant 2006;6:398-403.

View Dr. Lederer's full list of publications from PubMed